On September 4, 2026, the U.S. Food and Drug Administration announced immediate actions intended to mitigate a potential shortage of neonatal starter parenteral nutrition (PN) products. The agency took these steps after receiving concerns from children's hospitals about continued access to starter PN, which delivers essential nutrients intravenously to premature and critically ill newborns unable to feed orally or by tube.
The release notes that certain standardized neonatal starter PN products were discontinued following the permanent shutdown of two outsourcing facilities. To help prevent disruptions in patient care while longer-term solutions are identified, the FDA issued an immediately-in-effect guidance document titled Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates. The guidance articulates the agency’s temporary regulatory and enforcement priorities related to compounding specified parenteral nutrition drug products.
The guidance is intended to support continued access to starter PN during a transition period. It specifies the FDA’s temporary regulatory and enforcement approach for entities compounding certain starter parenteral nutrition products for neonates. The stated purpose is to address potential supply gaps and to support hospitals that rely on these products for life-saving neonatal care.
The FDA described the policies as temporary and framed them as measures to help hospitals maintain access to critical nutrition drug products while the agency and stakeholders identify longer-term solutions.
The news release identifies the affected products as standardized starter parenteral nutrition formulations used soon after birth for premature and critically ill newborns. Concerns about continued access arose because two outsourcing facilities that manufactured certain standardized starter PN products are permanently shutting down, and those facilities discontinued production of those products.
Because starter PN is particularly important for newborns who need nutrition immediately after birth, the FDA determined that timely action was warranted to prevent potential harm from supply disruptions.
The guidance addresses compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. It explains the agency’s temporary regulatory and enforcement priorities for certain state-licensed pharmacies, federal facilities and outsourcing facilities that compound the specified parenteral drug products.
The release does not provide procedural details of the compounding practices or the specific content of the temporary policies beyond their intended purpose and regulatory scope. For full text and operational detail, the FDA referenced the guidance document by title.
Acting FDA Commissioner Kyle Diamantas, J.D., is quoted emphasizing the agency’s commitment to using regulatory tools to prevent supply chain gaps from threatening patient care and noting collaboration with healthcare providers and industry partners to ensure access for vulnerable populations.
Michael Davis, M.D., Ph.D., Acting Center Director of the FDA’s Center for Drug Evaluation and Research, is quoted highlighting the importance of starter parenteral nutrition for premature and critically ill newborns and describing the temporary policies as intended to help hospitals maintain access to this life-saving nutrition during the transition period.
The guidance aims to help hospitals continue to procure or obtain access to compounded starter PN products during the interim. It applies to state-licensed pharmacies, federal facilities and outsourcing facilities compounding under sections 503A and 503B. The release indicates these temporary policies are meant to assist hospitals while the FDA and partners pursue longer-term remedies to the supply situation.
The announcement does not list specific facilities, product brand names, or step-by-step compounding instructions. It focuses on the regulatory posture and intent to reduce the risk of care interruptions for newborns dependent on parenteral nutrition.
The FDA stated it will continue to monitor current and anticipated supply needs and will assess whether additional actions are required as the situation evolves. Contact information for media and consumer inquiries was provided in the release. The agency also invited comment via an FDA request-for-comment link referenced in the announcement.
Content in this summary is based solely on the FDA press release dated September 4, 2026, and the immediately-in-effect guidance referenced therein. Details beyond what the FDA reported, including specific compounding instructions, individual product listings, or further operational steps, were not provided in the source document.